Vertex Pharma (VRTX) Tops Q3 EPS by 30c; raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Vertex (VRTX) PT Raised to $451 at RBC Capital
November 5, 2024 7:00 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Vertex (NASDAQ: VRTX) to $451.00 (from $437.00) while maintaining a Sector Perform rating.
The analyst comments "CF beat and raise shows the continued health of the company's core franchise and is likely to perpetuate... More
